<DOC>
	<DOCNO>NCT00197028</DOCNO>
	<brief_summary>GSK Biologicals develop partnership Program Appropriate Technology Health ( PATH ) Malaria Vaccine Initiative candidate malaria vaccine routine immunization infant child live malaria endemic area . The vaccine would offer protection malaria disease due parasite Plasmodium falciparum . The vaccine would also provide protection infection hepatitis B virus ( HBV ) . This trial carry follow demonstration efficacy previous version malaria candidate vaccine child Mozambique : , vaccine demonstrate approximately 30 % efficacy clinical episode malaria approximately 58 % efficacy severe malaria disease . In order integrate malaria vaccine Expanded Program Immunization ( EPI ) regimen , malaria-endemic region , trial , 0.5 ml dose GSK 257049 vaccine develop . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Examine Safety Immune Responses GSK 257049 Vaccine When Administered Infants Living Malaria-endemic Region</brief_title>
	<detailed_description>All infant participate phase I/IIb study receive TETRActHib ( license diphtheria-tetanus-pertussis Haemophilus influenzae vaccine manufacture Aventis Pasteur ) IM injection right thigh 8 , 12 , 16 week ; They randomize receive either candidate malaria vaccine , GSK 257049 vaccine ( 0.5 ml dose ) Engerix-B ( license hepatitis B vaccine manufacture GSK Biologicals ) IM injection leave thigh 10 , 14 , 18 week . Infants followed-up daily 7 day vaccine dose evaluation safety reactogenicity . There 14-day follow-up period dose TETRActHib Dose 1 Dose 2 GSK 257049 vaccine Engerix-B , one month follow-up period Dose 3 GSK 257049 vaccine Engerix-B reporting unsolicited symptom . Serious adverse event record throughout 14 month study period . A small amount blood ( 2 ml = 1/2 teaspoon ) obtain four different time point measure immune response elicit vaccine administer study period . Preliminary indication vaccine efficacy age group establish actively monitor infection Plasmodium falciparum .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female infant 6 12 week age time first vaccination . Written inform consent obtain parent ( ) guardian ( ) subject Free obvious health problem establish medical history clinical examination enter study . Born mother hepatitis B surface antigen ( HBsAg ) negative human immunodeficiency virus ( HIV ) negative . Born normal gestation period ( 36 42 week ) . Subjects investigator believe parents/guardians comply requirement protocol enrol study . Bacillus CalmetteGu√©rin tuberculosis vaccine ( BCG ) administration within one week propose administration study vaccine . Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period . Administration immunoglobulins and/or blood product since birth plan administration study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth Any chronic drug therapy continue study period . Previous vaccination diphtheria , tetanus , pertussis , Haemophilus influenzae type b hepatitis B vaccine . Major congenital abnormality . Serious acute chronic illness determine clinical , physical examination laboratory screen test Any medically diagnose suspected immunodeficient condition base medical history physical examination A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . History neurological disorder seizure . Maternal death . Hemoglobin &lt; 80 g/L Simultaneous participation clinical trial . Same sex twin Any finding investigator feel would increase risk adverse outcome participation trialModerate malnutrition screen</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>